Comparative pharmacokinetics of ofloxacin and ciprofloxacin. 1989

J S Wolfson, and D C Hooper
Medical Services, Massachusetts General Hospital, Boston 02114.

Review of publications in which the pharmacokinetics of ofloxacin and ciprofloxacin were compared directly indicates that although similar in many respects, these fluoroquinolones exhibit three differences that may be important clinically. First, ofloxacin is more completely absorbed, achieves higher peak serum concentrations, and has a longer terminal elimination half-life, which result in a fivefold greater area under the curve than that of ciprofloxacin when similar doses are orally administered. Ofloxacin's more favorable pharmacokinetic profile seems to compensate at least in part for the greater activity of ciprofloxacin against gram-negative bacilli in vitro. Second, ofloxacin is eliminated almost entirely via the kidneys, whereas ciprofloxacin is eliminated via both the kidneys and non-renal routes. This suggests that ciprofloxacin may be preferable for patients with variable renal function, whereas ofloxacin may be preferable for patients receiving dialysis because of the need for less frequent administration. Third, concomitant use of ciprofloxacin with either theophylline or caffeine decreases elimination and thereby results in elevated serum concentrations of these methylxanthine derivatives. Because ofloxacin does not cause clinically significant alterations in the pharmacokinetics of either theophylline or caffeine, it may be preferable for patients using these concomitantly.

UI MeSH Term Description Entries
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D015242 Ofloxacin A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. DL-8280,DR-3355,Hoe-280,ORF-28489,Ofloxacin Hydrochloride,Ofloxacine,Ru-43280,Tarivid,DL 8280,DL8280,DR 3355,DR3355,Hoe 280,Hoe280,ORF 28489,ORF28489,Ru 43280,Ru43280

Related Publications

J S Wolfson, and D C Hooper
September 1988, The Journal of antimicrobial chemotherapy,
J S Wolfson, and D C Hooper
October 1987, The Journal of antimicrobial chemotherapy,
J S Wolfson, and D C Hooper
April 1993, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
J S Wolfson, and D C Hooper
January 1994, The Journal of antimicrobial chemotherapy,
J S Wolfson, and D C Hooper
January 1990, Scandinavian journal of infectious diseases. Supplementum,
J S Wolfson, and D C Hooper
November 1999, The Journal of antimicrobial chemotherapy,
J S Wolfson, and D C Hooper
January 2006, Chemotherapy,
J S Wolfson, and D C Hooper
March 1998, Biopharmaceutics & drug disposition,
J S Wolfson, and D C Hooper
January 1990, Presse medicale (Paris, France : 1983),
J S Wolfson, and D C Hooper
June 1999, Journal of veterinary pharmacology and therapeutics,
Copied contents to your clipboard!